Darwin AG: Revenue and Earnings Forecast 2026–2029

Munich, 23/01/2026 (pta008/23.01.2026/10:00 UTC+1)

Darwin AG (ISIN DE000A3C35W0) expects sales revenues of more than €65 million for the 2026 financial year, corresponding to growth of at least 18% compared to the financial year 2025, and a positive EBIT.

From the 2027 financial year onwards, the Group anticipates a significant acceleration in growth. Based on the current business plan, revenues and EBIT for the 2027–2029 financial years are expected to exceed the following minimum values:

This highly dynamic growth is driven primarily by the segment genetic tests and personalized products and is influenced particularly by the international major projects 10X Health and M42 (Abu Dhabi). Earnings development follows not only the generally very strong margins in this segment but also the decreasing significance of fixed costs as revenue grows.

"Continued growth in the 2026 financial year confirms the trend of recent years" commented CEO Dr. Daniel Wallerstorfer. "The excellent outlook for the 2027–2029 financial years further demonstrates the unique selling points of our products in international competition" added the company founder and CEO.

The publication of the preliminary 2025 consolidated financial figures is scheduled for mid-February 2026. The publication of the audited consolidated financial statements is expected to follow mid-May 2026.

About Darwin AG

The "Darwin Group" (i.e., Darwin AG including its subsidiaries), headquartered in Munich (Germany), is a European healthcare and biotechnology company, particularly active in the field of human genetics. The genetic analyses carried out in the company's own laboratory are used in the diagnosis, treatment, and prevention of diseases, as well as in the production of individually designed nutritional supplements and cosmetics. Darwin also acts as a partner for physicians, therapists, pharmacists, nutritionists, and fitness trainers, helping—through analysis of a patient's or customer's genetic predisposition—to provide treatment or support that is as optimal as possible for their needs. In addition, Darwin invests in innovative companies in the biotech, healthcare, and life sciences sectors.

(end)

Emitter:	Darwin AG Brienner Straße 7 80333 München Germany
Contact Person:	Daniel Wallerstorfer
Phone:	+49 89 20 500 450
E-Mail:	investor.relations@darwin-biotech.com
Website:	www.darwin-biotech.com
ISIN(s):	DE000A3C35W0 (Share)
Stock Exchange(s):	Free Market in Frankfurt, Munich (m:access)